WO1993019771A1 - Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires - Google Patents
Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires Download PDFInfo
- Publication number
- WO1993019771A1 WO1993019771A1 PCT/JP1993/000368 JP9300368W WO9319771A1 WO 1993019771 A1 WO1993019771 A1 WO 1993019771A1 JP 9300368 W JP9300368 W JP 9300368W WO 9319771 A1 WO9319771 A1 WO 9319771A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- csf
- stimulating factor
- granulocyte colony
- administration
- Prior art date
Links
- AWYMFBJJKFTCFO-UHFFFAOYSA-N C(C1)C2C1CCC2 Chemical compound C(C1)C2C1CCC2 AWYMFBJJKFTCFO-UHFFFAOYSA-N 0.000 description 1
- 0 C1C(C2C#CCC2)C2(*CC3)C3C12 Chemical compound C1C(C2C#CCC2)C2(*CC3)C3C12 0.000 description 1
- ZCTVSCOGLXXLNI-UHFFFAOYSA-N C1SC2C1CCC2 Chemical compound C1SC2C1CCC2 ZCTVSCOGLXXLNI-UHFFFAOYSA-N 0.000 description 1
- XAZKFISIRYLAEE-UHFFFAOYSA-N CC1CC(C)CC1 Chemical compound CC1CC(C)CC1 XAZKFISIRYLAEE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- Sugars include lactose, sucrose, sucrose, fructose, D-sorbitol, D-mannitol, inositol, and sucrose.
- Minerals include magnesium stearate, calcium phosphate, calcium hydrogen phosphate, magnesium carbonate, sodium chloride, calcium sulfate, and the like.
- organic acids include succinic acid, tartaric acid, citric acid, fumaric acid, lingic acid, gluconic acid, and glucuronic acid.
- Cellulose includes microcrystalline cellulose, methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxypropylcellulose, carboxypropylcellulose, and carboxymethylcellulose sodium. You.
- Example Granulocyte colony stimulating factor 0.375 sodium sodium deoxycholate
- the formulation of the present invention of Example 32 was prepared using a phosphate buffer at a concentration of 10 mM.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Préparation administrable par voie nasale contenant, à titre d'ingrédient actif, un facteur de stimulation de colonies granulocytaires (G-CSF), une protéine physiologiquement active.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7160592 | 1992-03-27 | ||
JP4/71605 | 1992-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993019771A1 true WO1993019771A1 (fr) | 1993-10-14 |
Family
ID=13465457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000368 WO1993019771A1 (fr) | 1992-03-27 | 1993-03-26 | Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993019771A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022065860A1 (fr) * | 2020-09-24 | 2022-03-31 | 충북대학교 산학협력단 | Préparation pouvant être inhalée comprenant du nafamostat ou du camostat |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01132532A (ja) * | 1987-10-15 | 1989-05-25 | Syntex Usa Inc | 粉末形態ポリプペチド類の経鼻投与 |
JPH02104531A (ja) * | 1988-10-14 | 1990-04-17 | Toyo Jozo Co Ltd | 経鼻投与用生理活性ペプチド組成物 |
WO1992011022A1 (fr) * | 1990-12-25 | 1992-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preparation pharmaceutique destinee a une administration par voie nasale |
-
1993
- 1993-03-26 WO PCT/JP1993/000368 patent/WO1993019771A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01132532A (ja) * | 1987-10-15 | 1989-05-25 | Syntex Usa Inc | 粉末形態ポリプペチド類の経鼻投与 |
JPH02104531A (ja) * | 1988-10-14 | 1990-04-17 | Toyo Jozo Co Ltd | 経鼻投与用生理活性ペプチド組成物 |
WO1992011022A1 (fr) * | 1990-12-25 | 1992-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preparation pharmaceutique destinee a une administration par voie nasale |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022065860A1 (fr) * | 2020-09-24 | 2022-03-31 | 충북대학교 산학협력단 | Préparation pouvant être inhalée comprenant du nafamostat ou du camostat |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3249147B2 (ja) | 生理活性蛋白含有経口製剤 | |
EP1093818B1 (fr) | Preparation en poudre pour administration par les muqueuses | |
EP0566135A1 (fr) | Composition transmucosale contenant un peptide et un dérivé de la cytidine | |
EP3603660B1 (fr) | Facteur 21 de croissance des fibroblastes humains mutants à action prolongée pour le traitement de la stéatohépatite non alcoolique | |
JP2006502969A (ja) | 内因性性腺刺激ホルモン産生の増強 | |
JP2012001558A (ja) | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 | |
JPH08245417A (ja) | 鼻内投与のための薬学的非無機塩類液剤 | |
JP2000504696A (ja) | 安定化された成長ホルモン処方物およびその製造方法 | |
EP0434625B1 (fr) | IGF-I pour le traitement des effets secondaires dans le traitement par stéroides | |
TW202400219A (zh) | 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物 | |
US11007178B2 (en) | Methods and uses of Nampt activators for treatment of diabetes, cardiovascular diseases, and symptoms thereof | |
US8058236B2 (en) | Aqueous inhalation pharmaceutical composition | |
JPH10505580A (ja) | ムラミルペプチド化合物の使用 | |
US6623732B1 (en) | Pharmaceutical formulation for nasal administration | |
JP2004506017A (ja) | 抗真菌剤組合せ使用 | |
WO1993019771A1 (fr) | Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires | |
US20090022684A1 (en) | Methods for hematopoietic stimulation | |
EP4464331A1 (fr) | Composition pharmaceutique stable d'agoniste de récepteurs, son procédé de préparation et son application | |
KR20220097360A (ko) | 수유 개선을 위한 메로토신의 비강내 투여 | |
JPH08198772A (ja) | 顆粒球コロニー刺激因子含有粉末経鼻投与製剤 | |
US20080075691A1 (en) | Permucosal Composition and Method of Improving Permucosal Absorption | |
US6228836B1 (en) | Permucous preparation | |
JPH01501708A (ja) | アミノ酸の経鼻投与 | |
WO2024222920A1 (fr) | Préparation pharmaceutique pour administration intranasale et son procédé de préparation | |
JPH10273448A (ja) | アトピー性疾患治療のための口腔内投与用治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |